Your browser doesn't support javascript.
loading
Current trends on cannabidiol delivery systems: where are we and where are we going?
Ramalho, Ízola Morais de Medeiros; Pereira, Daniel Torres; Galvão, Giovanna Brunelly Lima; Freire, Danielle Teixeira; Amaral-Machado, Lucas; Alencar, Éverton do Nascimento; Egito, Eryvaldo Socrates Tabosa do.
Afiliação
  • Ramalho ÍMM; Graduate Program in Health Sciences (Ppgcsa), Federal University of Rio Grande Do Norte (UFRN), Natal, Brazil.
  • Pereira DT; Graduate Program in Health Sciences (Ppgcsa), Federal University of Rio Grande Do Norte (UFRN), Natal, Brazil.
  • Galvão GBL; Department of Pharmacy, Federal University of Rio Grande Do Norte (UFRN), Natal, Brazil.
  • Freire DT; Department of Pharmacy, Federal University of Rio Grande Do Norte (UFRN), Natal, Brazil.
  • Amaral-Machado L; Graduate Program in Health Sciences (Ppgcsa), Federal University of Rio Grande Do Norte (UFRN), Natal, Brazil.
  • Alencar ÉDN; Department of Pharmacy, Federal University of Rio Grande Do Norte (UFRN), Natal, Brazil.
  • Egito ESTD; Department of Pharmacy, Federal University of Rio Grande Do Norte (UFRN), Natal, Brazil.
Expert Opin Drug Deliv ; 18(11): 1577-1587, 2021 11.
Article em En | MEDLINE | ID: mdl-34253133
INTRODUCTION: Cannabidiol (CBD), a phytocannabinoid from Cannabis sativa, has several therapeutic properties. However, its high lipophilicity, metabolization, and instability impair its bioavailability and translational use in clinical settings. Several advanced drug delivery systems (ADDSs) have been evaluated as CBD carriers to overcome these drawbacks. These systems can improve the CBD dissolution profile, protect it against metabolization, and produce a site-specific release, increasing its bioavailability and making CBD administration clinically effective. AREAS COVERED: This review summarizes scientific reports on cannabidiol advanced delivery systems (CBD-ADSs) that have been (i) developed, and (ii) applied therapeutically; reports published in the main scientific databases until January 2020 were included. Studies without experimental data and/or published in languages other than English were excluded. Moreover, pharmaceutical technology tools in CBD therapeutic use have been discussed, emphasizing the clinical translation of CBD carrier use. EXPERT OPINION: Studies reporting CBD-ADS use for medicinal applications were reviewed and revealed multifaceted systems that can overcome the physicochemical drawbacks of CBD and improve its biological activities. Therefore, researchers concluded that the developed CBD-ADS can be used as an alternative to traditional formulations because they show comparable or superior effectiveness in treatment protocols. Although several criteria remain to be met, our findings emphasize the potential of CBD-ADSs for translational therapeutics, particularly for neurological-disorders.
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Canabidiol / Cannabis / Doenças do Sistema Nervoso Tipo de estudo: Guideline Idioma: En Revista: Expert Opin Drug Deliv Assunto da revista: FARMACOLOGIA / TERAPIA POR MEDICAMENTOS Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Brasil País de publicação: Reino Unido
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Canabidiol / Cannabis / Doenças do Sistema Nervoso Tipo de estudo: Guideline Idioma: En Revista: Expert Opin Drug Deliv Assunto da revista: FARMACOLOGIA / TERAPIA POR MEDICAMENTOS Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Brasil País de publicação: Reino Unido